The second part of our conversation with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and ...

FYB202 is an interleukin inhibitor that can be used in dermatology to treat psoriasis and in gastroenterology to treat chronic inflammatory bowel disease. The biosimilar received marketing ...

Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

Scientific publicationFormycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin 20.02.2025 / 06:30 CET/CESTThe issuer is solely responsible for the content of ...

In November, Amneal received FDA approval for exenatide, its first generic injectable glucagon-like peptide-1 (GLP-1) agonist ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving the way for its US launch. Celltrion’s Stelara biosimilar ustekinumab ...

As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & Johnson is confident it can eke out revenue growth this year despite the ...

This outlook comes despite facing significant challenges, including the introduction of Stelara biosimilars, substantial foreign exchange headwinds, and changes to Medicare Part D that are ...

Then last month, Amgen brought to the market a knockoff of Johnson & Johnson immunology powerhouse Stelara. In the last nine weeks of last year, Amgen’s Eylea biosimilar, Pavblu, generated $31 ...